RESUMO
PURPOSE: Intravenous glucocorticoids (ivGCs) given as 12-weekly infusions are the first-line treatment for moderate-to-severe and active Graves' orbitopathy (GO), but they are not always effective. In this study, we evaluated whether response at 6 weeks correlated with outcomes at 12 (end of intervention) and 24 (follow-up) weeks, particularly in patients initially unresponsive. METHODS: Our database (Bartalena et al. J Clin Endocrinol Metab 97:4454-4463, 10), comprising 159 patients given three different cumulative doses of methylprednisolone (2.25, 4.98, 7.47 g) was analyzed, pooling data for analyses. Responses at 6 weeks were compared with those at 12 and 24 weeks using three outcomes: overall ophthalmic involvement [composite index (CI)]; quality of life (QoL); Clinical Activity Score (CAS). Responses were classified as "Improved", "Unchanged", "Deteriorated", compared to baseline. RESULTS: Deteriorated patients at 6 weeks for CI (n = 8) remained in the same category at 12 weeks and 7/8 at 24 weeks. Improved patients at 6 weeks for CI (n = 51) remained in the same category in 63% and 53% of cases at 12 and 24 weeks, respectively. Unchanged patients at 6 weeks (n = 100) eventually improved in 28% of cases (CI), 58% (CAS), 32% (QoL). There was no glucocorticoid dose-dependent difference in the influence of early response on later outcomes. CONCLUSIONS: Patients who deteriorate at 6 weeks after ivGCs are unlikely to benefit from continuing ivGCs. Patients unresponsive at 6 weeks still have a significant possibility of improvement later. Accordingly, they may continue ivGC treatment, or, alternatively, possibly stop ivGCs and be switched to a second-line treatment.
Assuntos
Glucocorticoides/administração & dosagem , Oftalmopatia de Graves/tratamento farmacológico , Qualidade de Vida , Índice de Gravidade de Doença , Administração Intravenosa , Seguimentos , Humanos , Resultado do TratamentoRESUMO
OBJECTIVE: Struma ovarii is a monodermal teratoma composed of thyroid tissue, representing 0.85 to 1.3% of ovarian tumors. The objective of the present study is to report a continuous series of struma ovarii, with a comprehensive analysis of the literature. METHODS: A retrospective study in the gynecological surgery department of Hôpital Femme-Mère-Enfant (Hospices Civils de Lyon, Lyon, France) assessed a continuous series of struma ovarii from the Lyon East Pathology Center database. Clinical and biological, imaging and pathological aspects were analyzed and the various forms of treatment described. RESULTS: We identified 7 patients with struma ovarii from March 2008 to April 2015. Mean patient age was 49.7 years (28-70years). Three patients had a history of thyroid disease. CA-125 was elevated (51IU/mL) in only 1 patient. MRI and ultrasound imaging did not enable diagnosis of struma ovarii, which depended on pathologic examination. Conservative surgery for cystectomy or oophorectomy was performed for patients wishing to become pregnant (71%); nonconservative hysterectomy was performed in postmenopausal women (29%). CONCLUSIONS: Struma ovarii is a rare, often asymptomatic condition in which diagnosis is difficult. Few series are described in the literature. Here we propose a management model for struma ovarii. Revision surgery and adjuvant therapy is indicated in case of malignant struma ovarii.
Assuntos
Neoplasias Ovarianas/patologia , Neoplasias Ovarianas/cirurgia , Estruma Ovariano/patologia , Estruma Ovariano/cirurgia , Adulto , Idoso , Cistectomia , Feminino , França , Humanos , Histerectomia , Imageamento por Ressonância Magnética , Pessoa de Meia-Idade , Ovariectomia , Estudos Retrospectivos , Doenças da Glândula Tireoide/complicações , UltrassonografiaRESUMO
The aim of follow-up of differentiated thyroid carcinoma (CTD) is the assessment of remission, and, in further steps, the early recognition of patients who develop a recurrence. Tools for the follow-up of CTD include the assessment of thyroglobulin and imaging procedures. Thyroglobulin (Tg) is a strong marker of persistent or recurrent disease, but it must be known that Tg antibodies may give falsely low Tg concentration. TSH stimulation, mainly by the mean of recombinant human TSH, improves the sensitivity of Tg determination. New highly sensitive assays may preclude the need for TSH stimulation, at least in some situations. In the last decades, (131)iodine whole body scan gave place to neck ultrasonography (US) as the most performing imaging procedure in the follow-up of CTD. Criteria to identify cervical lymph node suspect of metastasis have been described, and standardized procedures proposed. Finally, the proof of tumoral invasion is brought by cytological analysis of fine needle biopsies of suspicious lymph nodes. (18)FDG PET is a valuable tool for diagnosis and prognosis in metastatic patients, especially with negative (131)I WBS. Initial response to therapy, assessed by Tg determination and neck US, allows re-stratification of the risk of relapse. According to this "reassessed risk", adapted rhythms and modalities of follow-up have been recently proposed.
Assuntos
Neoplasias da Glândula Tireoide/patologia , Neoplasias da Glândula Tireoide/terapia , Autoanticorpos/sangue , Biomarcadores Tumorais/sangue , Biópsia por Agulha Fina , Diagnóstico por Imagem , Reações Falso-Negativas , Seguimentos , Humanos , Metástase Linfática/diagnóstico , Pescoço/diagnóstico por imagem , Recidiva Local de Neoplasia/diagnóstico , Tomografia por Emissão de Pósitrons , Indução de Remissão , Fatores de Risco , Tireoglobulina/sangue , Tireoglobulina/imunologia , Tireotropina/farmacologia , UltrassonografiaRESUMO
BACKGROUND: Adrenocortical carcinoma (ACC) is a rare cancer for which little level evidence exists to guide management. (18)F-FDG PET ((18)F-fluorodeoxyglucose positron emission tomography) is an increasingly used diagnostic tool in patients with suspicious or indeterminate adrenal tumors. In some other solid tumors, (18)F-FDG PET may offer prognostic information that can guide optimal patient treatment. The aim of the present study was to evaluate whether preoperative (18)F-FDG PET based on SUVs assessments has a prognostic value in ACC patients. METHODS: A retrospective analysis was performed in patients who underwent (18)F-FDG PET/CT for the evaluation of ACC. Inclusion criteria were an unequivocal diagnosis of ACC; all data from primary diagnosis available; (18)F-FDG PET/CT performed prior to surgery or other treatment of the primary tumor; a minimum of 6-months follow-up for surviving patients. All (18)F-FDG PET/CT procedures were reinterpreted in a blind fashion. RESULTS: Thirty-seven patients (23 without metastasis [M0], 14 with metastasis [M1]) fulfilled the study criteria. Median uptake values were tumor standardized uptake values (SUV)(max) = 11 (range: 3-56) and a tumor/liver SUV(max) ratio = 4.2 (range: 1.3-15). Median follow-up was 20 months. Although classic risk factors (tumoral stage, Weiss score) were associated with poor outcome, there was no correlation between primary tumor FDG uptake with overall survival (OS) and disease free survival (DFS) in M0 patients and with overall survival in M1 patients. (18)F-FDG uptake correlated inconsistently with sinister histological features, such as atypical mitoses or necrosis. CONCLUSIONS: At initial staging, primary tumor FDG uptake in ACC patients does not correlate with OS and DFS at 2 years. Patient prognosis and treatment strategy should not be based on uptake values.
Assuntos
Neoplasias do Córtex Suprarrenal/diagnóstico por imagem , Neoplasias do Córtex Suprarrenal/patologia , Fluordesoxiglucose F18 , Tomografia por Emissão de Pósitrons , Compostos Radiofarmacêuticos , Adulto , Idoso , Idoso de 80 Anos ou mais , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Estadiamento de Neoplasias , Prognóstico , Estudos Retrospectivos , Adulto JovemRESUMO
BACKGROUND: Optimal doses of i.v. glucocorticoids for Graves' orbitopathy (GO) are undefined. METHODS: We carried out a multicenter, randomized, double-blind trial to determine efficacy and safety of three doses of i.v. methylprednisolone in 159 patients with moderate to severe and active GO. Patients were randomized to receive a cumulative dose of 2.25, 4.98, or 7.47 g in 12 weekly infusions. Efficacy was evaluated objectively at 12 wk by blinded ophthalmologists and subjectively by blinded patients (using a GO specific quality of life questionnaire). Adverse events were recorded at each visit. RESULTS: Overall ophthalmic improvement was more common using 7.47 g (52%) than 4.98 g (35%; P = 0.03) or 2.25 g (28%; P = 0.01). Compared with lower doses, the high-dose regimen led to the most improvement in objective measurement of ocular motility and in the Clinical Activity Score. The Clinical Activity Score decreased in all groups and to the least extent with 2.25 g. Quality of life improved most in the 7.47-g group, although not reaching statistical significance. No significant differences occurred in exophthalmos, palpebral aperture, soft tissue changes, and subjective diplopia score. Dysthyroid optic neuropathy developed in several patients in all groups. Because of this, differences among the three groups were no longer apparent at the exploratory 24-wk visit. Major adverse events were slightly more frequent using the highest dose but occurred also using the lowest dose. Among patients whose GO improved at 12 wk, 33% in the 7.47-group, 21% in the 4.98-group, and 40% in the 2.25-group had relapsing orbitopathy after glucocorticoid withdrawal at the exploratory 24-wk visit. CONCLUSIONS: The 7.47-g dose provides short-term advantages over lower doses. However, this benefit is transient and associated with slightly greater toxicity. The use of a cumulative dose of 7.47 g of methylprednisolone provides short-term advantage over lower doses. This may suggest that an intermediate-dose regimen be used in most cases and the high-dose regimen be reserved to most severe cases of GO.
Assuntos
Oftalmopatia de Graves/tratamento farmacológico , Metilprednisolona/administração & dosagem , Metilprednisolona/efeitos adversos , Administração Intravenosa , Adulto , Idoso , Anti-Inflamatórios/administração & dosagem , Anti-Inflamatórios/efeitos adversos , Relação Dose-Resposta a Droga , Método Duplo-Cego , Feminino , Oftalmopatia de Graves/epidemiologia , Humanos , Masculino , Pessoa de Meia-Idade , Órbita/efeitos dos fármacos , Órbita/patologia , Índice de Gravidade de Doença , Resultado do TratamentoRESUMO
PURPOSE: The purpose of the study was to assess prospectively the impact of recombinant human TSH (rhTSH) administration on positron emission tomography (PET)/computed tomography (CT) imaging in differentiated thyroid cancer patients who, after primary treatment, had a suppressed or stimulated serum thyroglobulin greater than 10 ng/ml and no radioactive iodine uptake consistent with thyroid cancer on a whole body scan. PATIENTS AND METHODS: PET/CT was performed before (basal PET) and 24-48 h after rhTSH administration (rhTSH-PET) in 63 patients (52 papillary and 11 follicular thyroid cancers). Images were blindly analyzed by two readers. The proposed treatment plan was prospectively assessed before basal PET, after basal PET, and again after rhTSH-PET. RESULTS: A total of 108 lesions were detected in 48 organs in 30 patients. rhTSH-PET was significantly more sensitive than basal PET for the detection of lesions (95 vs. 81%; P = 0.001) and tended to be more sensitive for the detection of involved organs (94 vs. 79%; P = 0.054). However, basal PET and rhTSH-PET did not have significantly different sensitivity for detecting patients with any lesions (49 vs. 54%; P = 0.42). Changes in treatment management plan occurred in 19% of the patients after basal PET. Lesions found only by rhTSH-PET contributed to an altered therapeutic plan in eight patients, among whom only four were true-positive on pathology (6%). CONCLUSION: The use of rhTSH for 2-[18F]-fluoro-2-deoxy-D-glucose-PET/CT significantly increased the number of lesions detected, but the numbers of patients in whom any lesion was detected were no different between basal and rhTSH-stimulated PET/CT scans. Treatment changes due to true positive lesions occurred in 6% of cases.
Assuntos
Adenocarcinoma Folicular/diagnóstico por imagem , Fluordesoxiglucose F18 , Neoplasia Residual/diagnóstico por imagem , Neoplasias da Glândula Tireoide/diagnóstico por imagem , Tireotropina , Adenocarcinoma Folicular/patologia , Adenocarcinoma Folicular/cirurgia , Adulto , Idoso , Variação Genética , Humanos , Pessoa de Meia-Idade , Metástase Neoplásica/diagnóstico por imagem , Metástase Neoplásica/patologia , Projetos Piloto , Tomografia por Emissão de Pósitrons , Compostos Radiofarmacêuticos , Proteínas Recombinantes , Sensibilidade e Especificidade , Neoplasias da Glândula Tireoide/patologia , Neoplasias da Glândula Tireoide/cirurgia , Tireoidectomia , Tomografia Computadorizada por Raios XAssuntos
Carcinoma/terapia , Neoplasias da Glândula Tireoide/terapia , Carcinoma/tratamento farmacológico , Carcinoma/patologia , Carcinoma/radioterapia , Carcinoma/cirurgia , Terapia Combinada , Humanos , Radioisótopos do Iodo/uso terapêutico , Recidiva Local de Neoplasia/prevenção & controle , Recidiva Local de Neoplasia/terapia , Testes de Função Tireóidea , Neoplasias da Glândula Tireoide/tratamento farmacológico , Neoplasias da Glândula Tireoide/patologia , Neoplasias da Glândula Tireoide/radioterapia , Neoplasias da Glândula Tireoide/cirurgiaRESUMO
Familial pituitary adenoma is a rare syndrome which may present either as isolated lesions, or in association with other endocrine tumors, for example in the frame of multiple endocrine neoplasia (MEN-1) or Carney complex (CNC). The most frequently described forms of familial isolated pituitary adenoma (FIPA) are familial somatotropinomas or prolactinomas. Recently, some cases of familial isolated somatotropinoma have been associated with germline mutations in the aryl hydrocarbon receptor interacting protein (AIP) gene. The present report shows heterogeneous FIPA with 3 subtypes of tumor in 3 individuals of the same family: somatotropinoma in the proband, giant prolactinoma in a brother, and gonadotroph cell macroadenoma in the father. A prospective survey also suggested the occurrence of a silent microadenoma in the proband's sister. Clinical screening was performed in the 3 affected members, the 4th suspected case, and 9 additional, asymptomatic relatives. They had no clinical evidence of associated endocrine lesion suggesting MEN-1 or CNC. Genetic screening for germline mutation of the MEN-1, the gene encoding the protein kinase A (PKA) type 1 alpha regulatory subunit (R1 alpha) (PRKAR1alpha) and AIP gene was negative in 2 affected members. In conclusion, these data suggest that familial pituitary adenomas can occur with a heterogeneous functional pattern that is distinguished from MEN-1 or CNC. The absence of mutation of the recently described AIP gene suggests the implication of other predisposing gene(s). Collaborative, multicentric studies are needed to further define the location of gene(s) involved in heterogeneous FIPA.
Assuntos
Adenoma/genética , Adenoma/fisiopatologia , Neoplasias Hipofisárias/genética , Neoplasias Hipofisárias/fisiopatologia , Adenoma/diagnóstico , Feminino , Predisposição Genética para Doença/genética , Testes Genéticos , Humanos , Masculino , Pessoa de Meia-Idade , Linhagem , Neoplasias Hipofisárias/diagnóstico , Polimorfismo de Nucleotídeo Único/genética , Proteínas Proto-Oncogênicas/genética , Receptores de Hidrocarboneto Arílico/genéticaRESUMO
Prognosis of differentiated thyroid cancer is favorable in the majority of cases. However, distant metastases occur in 10-15% of cases, predominantly in lungs and bones, especially in older patients exhibiting poorly differentiated forms or advanced stages. We report a case history of Hürthle cell thyroid carcinoma metastasized to the sigmoid colon. To the best of our knowledge, this location has never been described before. This case history illustrates the difficulties of diagnosis and treatment in patients whose metastases do not concentrate radioiodine. The interest of different imaging modalities, including fluoro-deoxy-glucose positron emission tomography scan and somatostatin receptor scintigraphy, is discussed.
Assuntos
Adenoma Oxífilo/patologia , Colo Sigmoide/patologia , Neoplasias do Colo/secundário , Neoplasias da Glândula Tireoide/patologia , Neoplasias do Colo/diagnóstico , Fluordesoxiglucose F18 , Humanos , Masculino , Pessoa de Meia-Idade , Tomografia por Emissão de Pósitrons , Tomografia Computadorizada por Raios XRESUMO
We report on a very rare case of hyperthyroidism due to multiple autonomously functioning bone metastasis of papillary thyroid cancer in a 79-year-old woman. This situation remains extremely uncommon, as shown by our review of the literature; only 47 similar cases have been published from 1946 to 2005. The pathogenic mechanism remains largely unknown in spite of several hypotheses (conjunction in volume and differentiation, auto-antibodies). Hyperthyroidism can be severe, and often T3 levels are markedly more elevated than T4 levels. Apart from hyperthyroidism caused by the hormone-production, clinical features are similar to that of usual metastatic thyroid cancer, occurring in elderly women in most cases, and of follicular type on pathology. Metastases mostly occur in bones and lungs. Treatment relies mainly on radio-iodine ((131)I), which is efficient on hormonal disorders, and prognosis appears to be correlated with the ability of the metastatic sites to concentrate radio-iodine.
Assuntos
Neoplasias Ósseas/secundário , Hipertireoidismo/etiologia , Neoplasias da Glândula Tireoide/patologia , Idoso , Neoplasias Ósseas/patologia , Feminino , Humanos , Metástase Neoplásica , Radiografia , Neoplasias da Glândula Tireoide/diagnóstico por imagem , Tiroxina/sangue , Tri-Iodotironina/sangueRESUMO
OBJECTIVES AND METHOD: The discordance between test by urine dipstick (nitrites and leucocyte-esterase) and analysis in laboratory, with urinary culture on the same sample was studied in diabetic patients, from October 2000 to May 2002, to eventually stop systematic laboratory test. The dipstick result (Clinitek 20 Bayer) was classified as "possibility of bacteriuria" if one of the two tests was positive. Bacteriuria was considered significant if the laboratory test result gave, at least 10(5) bacteria per mL, (one strain), and at least 10(4) leucocytes. The out point was the dipstick negative predictive value (NPV). RESULTS: The study included 683 patients. The dipstick result was "possibility of bacteriuria" in 153 cases (22.4%). Thirty-nine bacteriuria (5.7%) were reported, including 2 dipstick false negatives. The NPV was 99.6% [IC 95% : 99.1-100]. CONCLUSION: The systematic laboratory tests were stopped.
Assuntos
Bacteriúria/diagnóstico , Complicações do Diabetes/diagnóstico , Testes Diagnósticos de Rotina , Procedimentos Desnecessários , Urina/microbiologia , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Bacteriúria/epidemiologia , Bacteriúria/etiologia , Bacteriúria/urina , Criança , Complicações do Diabetes/epidemiologia , Complicações do Diabetes/urina , Testes Diagnósticos de Rotina/estatística & dados numéricos , Suscetibilidade a Doenças , Reações Falso-Negativas , Feminino , França/epidemiologia , Glicosúria/epidemiologia , Hematúria/epidemiologia , Humanos , Corpos Cetônicos/urina , Contagem de Leucócitos , Masculino , Pessoa de Meia-Idade , Valor Preditivo dos Testes , Proteinúria/epidemiologia , Fitas Reagentes , Procedimentos Desnecessários/estatística & dados numéricos , Urina/citologiaRESUMO
A simple diastereoselective access to amino- and hydrazinocyclopentitols is described. The key step involves a cationic rearrangement of a meso bicyclic hydrazine, followed by two successive stereoselective hydroxylations. Both racemic compounds are micromolar alpha-mannosidase (Jack bean) inhibitors.
Assuntos
Ciclopentanos/síntese química , Inibidores Enzimáticos/síntese química , Hidrazinas/química , alfa-Manosidase/antagonistas & inibidores , Técnicas de Química Combinatória , Ciclopentanos/análise , Inibidores Enzimáticos/análise , Estrutura Molecular , EstereoisomerismoAssuntos
Hipertireoidismo/fisiopatologia , Hipotireoidismo/fisiopatologia , Complicações na Gravidez/fisiopatologia , Gravidez/fisiologia , Glândula Tireoide/fisiologia , Feminino , Feto/fisiologia , Doença de Graves/fisiopatologia , Humanos , Placenta/fisiologia , Glândula Tireoide/fisiopatologia , Tireotoxicose/fisiopatologiaRESUMO
Epidemiological studies, as well as animal models, indicate that iodine might be an immunogenic agent for the thyroid gland, at least in subjects predisposed to thyroid autoimmunity. This review presents data, either epidemiological or experimental, obtained in different conditions: constant and stable iodine status, either deficient, sufficient or excessive; long-term iodine prophylaxis; temporary supplementation with iodide (6-12 months) or iodised oil. Moreover, we also discuss data obtained in the general population, among subjects with euthyroid goiter, or autoimmune goiter, or even in women prone to post-partum thyroid diseases. It is concluded that the significant increase in the prevalence of autoimmune thyroid diseases in populations living in iodine sufficient areas should not prevent the implementation of the iodine prophylaxis.